Cell Therapy Manufacturing Market Synopsis

Cell Therapy Manufacturing Market Size Was Valued at USD 4.5 Billion in 2023, and is Projected to Reach USD 16.1 Billion by 2032, Growing at a CAGR of 15.2% From 2024-2032.

In other words, the Cell Therapy Manufacturing Market relates to the business industry focused on the manufacturing and marketing of therapeutic products from living cells. This involves cell acquisition, culture, growth and testing that forms part of regenerative medicine for diseases including but not limited to cancers and genetic disorders. These include autologous and allogeneic cell therapies, as well as their usage in oncology, immunology and in the practice of regenerative medicine. With the development of regenerative medicine, the need for cell therapy products remains higher as the biotechnology progresses and the public becomes aware of cellular processes in diseases’ mitigation.

•  The Cell Therapy Manufacturing Market is evolving rapidly as the population is aging, and chronic diseases are becoming more prevalent, alongside the development of regenerative medicines. Cell therapies are a new type of treatment that aims at healing the root of a problem as opposed to masking the symptoms: the main idea is individualized medicine. The increasing rate of diseases like cancer, autoimmune diseases and genetic disorders among people means that there must be advanced treatment and this cannot be accomplished without cell manufacturing. Moreover, current and potential investors include big pharmaceutical companies and academic research institutions invest more in research and development to create a pipeline of cell therapies.
• The market of stem cell therapy products and technologies is segmented based on type of therapy, autologous and allogeneic therapy. Due to the fact that autologous therapies have little to no risk in rejection from the patient’s immune system, they are making their way into the market. On the other hand, allogeneic therapies related to donor derived cells appear to offer possibilities of developing more solutions suited for larger communities of patients. There are also changes in manufacturing technology, cell culture automation, and bioreactors, which have led to optimisation of the process and shrinkage of costs. New regulations in healthcare are also being put in place to cover the use of these innovative therapies in ensuring that patient safety is met hence increasing growth in the market.

Cell Therapy Manufacturing Market Trend Analysis

Advancements in Manufacturing Technologies

• An emerging trend of the Cell Therapy Manufacturing Market is the continued development of manufacturing technologies designed to enhance productivity and capacity. Modern advances like automation, being able to create closed loop process, and monitoring processes as they occur are changing classical conceptions of manufacturing. Sophisticated tools are beginning to be incorporated into the cell processing processes in order to reduce variability and human involvement where possible. Other fields links with cell culture and cell processing involve artificial intelligence and machine learning in performance prediction and reduction in manufacturing time. These improvements are not only beneficial in improving aspects of cell therapies but also allow manufacturers to address the greater demand for cell therapies in a cost efficient manner. Such technological improvements are anticipated to define the future of cell therapy production as a market continues to gain increasing maturity, thus providing accessibility to more patients globally.

Growing Demand for Regenerative Medicine

• The Cell Therapy Manufacturing Market serves a highly promising market owing to the emergence of regenerative medicine as the key growth driver. With more research being conducted about the ability of organ cell therapies in treating numerous diseases and illnesses, people have increased their longing for capable regenerative medicine. Primarily, the progress in creating so-called ‘off the shelf’ cell therapies and in the gene editing technology known as CRISPR-Cas9 is raising new possibilities. They include basic ideas that make it possible to develop human universal stem donor cells which have the potential of tackling many diseases and at the same time reduce costs of manufacturing. In addition, biotechnology, research organizations and regulatory agencies’ collaborations are encouraging collective entity that are speeding up the process of moving discoveries from lab to patient care. This not only strengthens this development pipeline but also promotes quicker market release of fresh cell treatment therapies, which will make the industry develop rapidly in the next few years.

Cell Therapy Manufacturing Market Segment Analysis:

Cell Therapy Manufacturing Market Segmented on the basis of Therapy Type, Technology, Source and Application.

By Therapy Type, Allogenic Cell Therapy segment is expected to dominate the market during the forecast period

• On the basis of therapy type, the allogeneic cell therapy segment is expected to have the largest share in the Cell Therapy Manufacturing Market in the forecast period. Allogeneic therapies involve the use of cells from a third party, this means that off the shelf products can be developed with allogeneic cells ready for use by patients. This approach has many pulses as compared to the prior methods including scalability and possibility to treat a groups of patient at once without isolation of cell from the body.
• As people demand efficient, affordable treatment, genuinely derived allogeneic cell therapies are receiving increasing attention and interest, especially in cancer and autoimmune diseases. One of the biggest advantages is the achievement of the degree of product uniformity that improves manufacturing effectiveness and, in turn, decreases the cost of such therapies which will be interesting for both healthcare providers and patients. In addition, the updates in technologies and policies are escalating to drive the pace of having allogeneic products on the market at a faster rate. These factors are motivating the allogeneic cell therapy segment for strong market dominance in the future years.

By Technology, Genome Editing Technology segment expected to held the largest share

• On the basis of technology, the Cell Therapy Manufacturing Market is segmented as Genome editing technology, which has been considered as the largest segment in the forecast period. Genomic scrub tools like CRISPR-Cas9, ZFNs and TALENs have sought to create hereditary changes which has enhanced cell therapy. Consequently, this capability can be applied in rectification of genetic imperfections and improvement of cell functions, and design of better therapeutic interventions for inherited afflictions as well as different types of cancers.
• As personalized medicine attracts more attention, with the development of genome editing technologies and widely use of clinical trial on genomic editing, intensive investment has been made in this field. Besides, with the ability to establish related technologies to develop off-the-shelf therapy that can quickly be used by patients, the market standings of such technologies are enhanced. With improved technology in the near future the genome editing technology segment will be one of the fastest-growing segments in the cell therapy manufacturing industry.

Cell Therapy Manufacturing Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The Cell Therapy Manufacturing Market’s analysis in 2023 revealed that the North America region captured slightly more than 45% of the entire global market. This leadership can be attributed to the following factors; high research and development budget, strong regulation, and lots of renowned biotechnology and pharma industries. For example, the United States is home to many of the most recognized cell therapy manufactures that are pioneers of this novel technology and the leading participants in clinical trials. In addition to this, it enjoys a well-developed clinical research base, appropriately trained human capital, and access to technology to enable it to quickly translate this form of treatment to market. With the growing number of people seeking individualized and self-repairing medicine, North America is predicted to be holding the market in the near future.

Active Key Players in the Cell Therapy Manufacturing Market

• Amgen (United States)
• AstraZeneca (United Kingdom)
• Bluebird Bio (United States)
• Bristol Myers Squibb (United States)
• Celgene (United States)
• Celyad Oncology (Belgium)
• Fate Therapeutics (United States)
• Gilead Sciences (United States)
• Kite Pharma (United States)
• Miltenyi Biotec (Germany)
• Novartis (Switzerland)
• Regeneron Pharmaceuticals (United States)
• Roche (Switzerland)
• Stemcell Technologies (Canada)
• Vericel Corporation (United States), Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cell Therapy Manufacturing Market by Therapy Type
 4.1 Cell Therapy Manufacturing Market Snapshot and Growth Engine
 4.2 Cell Therapy Manufacturing Market Overview
 4.3 Allogenic Cell Therapy
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Allogenic Cell Therapy: Geographic Segmentation Analysis
 4.4 Autologous Cell Therapy
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Autologous Cell Therapy: Geographic Segmentation Analysis

Chapter 5: Cell Therapy Manufacturing Market by technology
 5.1 Cell Therapy Manufacturing Market Snapshot and Growth Engine
 5.2 Cell Therapy Manufacturing Market Overview
 5.3 cell Technology
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 cell Technology: Geographic Segmentation Analysis
 5.4 Cell Immortalization Technology
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Cell Immortalization Technology: Geographic Segmentation Analysis
 5.5 Viral Vector Technology
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Viral Vector Technology: Geographic Segmentation Analysis
 5.6 Genome Editing Technology
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Genome Editing Technology: Geographic Segmentation Analysis
 5.7 Cell Plasticity Technology
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Cell Plasticity Technology: Geographic Segmentation Analysis
 5.8 3D Technology
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 3D Technology: Geographic Segmentation Analysis

Chapter 6: Cell Therapy Manufacturing Market by Source
 6.1 Cell Therapy Manufacturing Market Snapshot and Growth Engine
 6.2 Cell Therapy Manufacturing Market Overview
 6.3 IPSC
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 IPSC: Geographic Segmentation Analysis
 6.4 Bone Marrow
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Bone Marrow: Geographic Segmentation Analysis
 6.5 Umbilical Cord
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Umbilical Cord: Geographic Segmentation Analysis
 6.6 Adipose Tissues
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Adipose Tissues: Geographic Segmentation Analysis
 6.7 Neural Stem
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Neural Stem: Geographic Segmentation Analysis

Chapter 7: Cell Therapy Manufacturing Market by Application
 7.1 Cell Therapy Manufacturing Market Snapshot and Growth Engine
 7.2 Cell Therapy Manufacturing Market Overview
 7.3 Musculoskeletal
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Musculoskeletal: Geographic Segmentation Analysis
 7.4 Cardiovascular
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Cardiovascular: Geographic Segmentation Analysis
 7.5 Gastrointestinal
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Gastrointestinal: Geographic Segmentation Analysis
 7.6 Neurological
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Neurological: Geographic Segmentation Analysis
 7.7 Oncology
  7.7.1 Introduction and Market Overview
  7.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.7.3 Key Market Trends, Growth Factors and Opportunities
  7.7.4 Oncology: Geographic Segmentation Analysis
 7.8 Dermatology
  7.8.1 Introduction and Market Overview
  7.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.8.3 Key Market Trends, Growth Factors and Opportunities
  7.8.4 Dermatology: Geographic Segmentation Analysis
 7.9 Others
  7.9.1 Introduction and Market Overview
  7.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.9.3 Key Market Trends, Growth Factors and Opportunities
  7.9.4 Others: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Cell Therapy Manufacturing Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 AMGEN (UNITED STATES)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 ASTRAZENECA (UNITED KINGDOM)
 8.4 BLUEBIRD BIO (UNITED STATES)
 8.5 BRISTOL MYERS SQUIBB (UNITED STATES)
 8.6 CELGENE (UNITED STATES)
 8.7 CELYAD ONCOLOGY (BELGIUM)
 8.8 FATE THERAPEUTICS (UNITED STATES)
 8.9 GILEAD SCIENCES (UNITED STATES)
 8.10 KITE PHARMA (UNITED STATES)
 8.11 MILTENYI BIOTEC (GERMANY)
 8.12 NOVARTIS (SWITZERLAND)
 8.13 REGENERON PHARMACEUTICALS (UNITED STATES)
 8.14 ROCHE (SWITZERLAND)
 8.15 STEMCELL TECHNOLOGIES (CANADA)
 8.16 VERICEL CORPORATION (UNITED STATES)

Chapter 9: Global Cell Therapy Manufacturing Market By Region
 9.1 Overview
 9.2. North America Cell Therapy Manufacturing Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Therapy Type
  9.2.4.1 Allogenic Cell Therapy
  9.2.4.2 Autologous Cell Therapy
  9.2.5 Historic and Forecasted Market Size By technology
  9.2.5.1 cell Technology
  9.2.5.2 Cell Immortalization Technology
  9.2.5.3 Viral Vector Technology
  9.2.5.4 Genome Editing Technology
  9.2.5.5 Cell Plasticity Technology
  9.2.5.6 3D Technology
  9.2.6 Historic and Forecasted Market Size By Source
  9.2.6.1 IPSC
  9.2.6.2 Bone Marrow
  9.2.6.3 Umbilical Cord
  9.2.6.4 Adipose Tissues
  9.2.6.5 Neural Stem
  9.2.7 Historic and Forecasted Market Size By Application
  9.2.7.1 Musculoskeletal
  9.2.7.2 Cardiovascular
  9.2.7.3 Gastrointestinal
  9.2.7.4 Neurological
  9.2.7.5 Oncology
  9.2.7.6 Dermatology
  9.2.7.7 Others
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Cell Therapy Manufacturing Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Therapy Type
  9.3.4.1 Allogenic Cell Therapy
  9.3.4.2 Autologous Cell Therapy
  9.3.5 Historic and Forecasted Market Size By technology
  9.3.5.1 cell Technology
  9.3.5.2 Cell Immortalization Technology
  9.3.5.3 Viral Vector Technology
  9.3.5.4 Genome Editing Technology
  9.3.5.5 Cell Plasticity Technology
  9.3.5.6 3D Technology
  9.3.6 Historic and Forecasted Market Size By Source
  9.3.6.1 IPSC
  9.3.6.2 Bone Marrow
  9.3.6.3 Umbilical Cord
  9.3.6.4 Adipose Tissues
  9.3.6.5 Neural Stem
  9.3.7 Historic and Forecasted Market Size By Application
  9.3.7.1 Musculoskeletal
  9.3.7.2 Cardiovascular
  9.3.7.3 Gastrointestinal
  9.3.7.4 Neurological
  9.3.7.5 Oncology
  9.3.7.6 Dermatology
  9.3.7.7 Others
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Cell Therapy Manufacturing Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Therapy Type
  9.4.4.1 Allogenic Cell Therapy
  9.4.4.2 Autologous Cell Therapy
  9.4.5 Historic and Forecasted Market Size By technology
  9.4.5.1 cell Technology
  9.4.5.2 Cell Immortalization Technology
  9.4.5.3 Viral Vector Technology
  9.4.5.4 Genome Editing Technology
  9.4.5.5 Cell Plasticity Technology
  9.4.5.6 3D Technology
  9.4.6 Historic and Forecasted Market Size By Source
  9.4.6.1 IPSC
  9.4.6.2 Bone Marrow
  9.4.6.3 Umbilical Cord
  9.4.6.4 Adipose Tissues
  9.4.6.5 Neural Stem
  9.4.7 Historic and Forecasted Market Size By Application
  9.4.7.1 Musculoskeletal
  9.4.7.2 Cardiovascular
  9.4.7.3 Gastrointestinal
  9.4.7.4 Neurological
  9.4.7.5 Oncology
  9.4.7.6 Dermatology
  9.4.7.7 Others
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Cell Therapy Manufacturing Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Therapy Type
  9.5.4.1 Allogenic Cell Therapy
  9.5.4.2 Autologous Cell Therapy
  9.5.5 Historic and Forecasted Market Size By technology
  9.5.5.1 cell Technology
  9.5.5.2 Cell Immortalization Technology
  9.5.5.3 Viral Vector Technology
  9.5.5.4 Genome Editing Technology
  9.5.5.5 Cell Plasticity Technology
  9.5.5.6 3D Technology
  9.5.6 Historic and Forecasted Market Size By Source
  9.5.6.1 IPSC
  9.5.6.2 Bone Marrow
  9.5.6.3 Umbilical Cord
  9.5.6.4 Adipose Tissues
  9.5.6.5 Neural Stem
  9.5.7 Historic and Forecasted Market Size By Application
  9.5.7.1 Musculoskeletal
  9.5.7.2 Cardiovascular
  9.5.7.3 Gastrointestinal
  9.5.7.4 Neurological
  9.5.7.5 Oncology
  9.5.7.6 Dermatology
  9.5.7.7 Others
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Cell Therapy Manufacturing Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Therapy Type
  9.6.4.1 Allogenic Cell Therapy
  9.6.4.2 Autologous Cell Therapy
  9.6.5 Historic and Forecasted Market Size By technology
  9.6.5.1 cell Technology
  9.6.5.2 Cell Immortalization Technology
  9.6.5.3 Viral Vector Technology
  9.6.5.4 Genome Editing Technology
  9.6.5.5 Cell Plasticity Technology
  9.6.5.6 3D Technology
  9.6.6 Historic and Forecasted Market Size By Source
  9.6.6.1 IPSC
  9.6.6.2 Bone Marrow
  9.6.6.3 Umbilical Cord
  9.6.6.4 Adipose Tissues
  9.6.6.5 Neural Stem
  9.6.7 Historic and Forecasted Market Size By Application
  9.6.7.1 Musculoskeletal
  9.6.7.2 Cardiovascular
  9.6.7.3 Gastrointestinal
  9.6.7.4 Neurological
  9.6.7.5 Oncology
  9.6.7.6 Dermatology
  9.6.7.7 Others
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Cell Therapy Manufacturing Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Therapy Type
  9.7.4.1 Allogenic Cell Therapy
  9.7.4.2 Autologous Cell Therapy
  9.7.5 Historic and Forecasted Market Size By technology
  9.7.5.1 cell Technology
  9.7.5.2 Cell Immortalization Technology
  9.7.5.3 Viral Vector Technology
  9.7.5.4 Genome Editing Technology
  9.7.5.5 Cell Plasticity Technology
  9.7.5.6 3D Technology
  9.7.6 Historic and Forecasted Market Size By Source
  9.7.6.1 IPSC
  9.7.6.2 Bone Marrow
  9.7.6.3 Umbilical Cord
  9.7.6.4 Adipose Tissues
  9.7.6.5 Neural Stem
  9.7.7 Historic and Forecasted Market Size By Application
  9.7.7.1 Musculoskeletal
  9.7.7.2 Cardiovascular
  9.7.7.3 Gastrointestinal
  9.7.7.4 Neurological
  9.7.7.5 Oncology
  9.7.7.6 Dermatology
  9.7.7.7 Others
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research